$2.88
3.03% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$2.88
-0.26 8.28% 1M
-0.10 3.36% 6M
+0.38 15.20% YTD
-0.25 7.99% 1Y
-75.32 96.32% 3Y
-35.72 92.54% 5Y
-158.72 98.22% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.09 3.03%
ISIN
US68235C1071
Symbol
OCX
Sector

Key metrics

Market capitalization $39.70m
Enterprise Value $34.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 33.44
P/S ratio (TTM) P/S ratio 38.92
P/B ratio (TTM) P/B ratio 1.75
Revenue (TTM) Revenue $1.02m
EBIT (operating result TTM) EBIT $-21.64m
Free Cash Flow (TTM) Free Cash Flow $-17.13m
Cash position $9.26m
EPS (TTM) EPS $-4.26
P/E forward negative
P/S forward 57.98
EV/Sales forward 49.81
Short interest 1.44%
Show more

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Oncocyte Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Oncocyte Corporation forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Oncocyte Corporation forecast:

Buy
33%
Hold
67%

Financial data from Oncocyte Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1.02 1.02
87% 87%
100%
- Direct Costs 2.01 2.01
79% 79%
197%
-0.98 -0.98
32% 32%
-96%
- Selling and Administrative Expenses 11 11
64% 64%
1,071%
- Research and Development Expense 8.34 8.34
55% 55%
818%
-20 -20
60% 60%
-1,984%
- Depreciation and Amortization 1.40 1.40
73% 73%
137%
EBIT (Operating Income) EBIT -22 -22
61% 61%
-2,122%
Net Profit -36 -36
43% 43%
-3,543%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncocyte Corporation Stock News

Neutral
MCAP MediaWire
about 2 months ago
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.
Neutral
GlobeNewsWire
about 2 months ago
IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test.
Neutral
Seeking Alpha
about 2 months ago
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
More Oncocyte Corporation News

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Joshua Riggs
Employees 46
Founded 2009
Website www.oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today